Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions

  • U. Bender Gerald Bronfman, McGill University
  • Y.S. Rho University of Hawaii Internal Medicine Program
  • I. Barrera Gerald Bronfman, McGill University
  • S. Aghajanyan Gerald Bronfman, McGill University
  • J. Acoba University of Hawaii Internal Medicine Program, University of Hawaii Cancer Center
  • P. Kavan Gerald Bronfman, McGill University
Keywords: Adjuvant chemotherapy, treatment duration, risk stratification, colorectal cancer

Abstract

Background To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, duration of therapy, and future directions.

Methods PubMed and medline were searched for literature pertinent to adjuvant chemotherapy in either stage ii or stage iii colorectal cancer.

Summary Locoregional disease, histopathology, age, laterality, and a number of other biologic and molecular markers appear to have a role in disease risk stratification. The duration of adjuvant therapy for stage iii disease can vary based on risk factors, but use of adjuvant therapy and duration of therapy in stage ii disease remain controversial. Future directions should include genomic assays and improved study design to provide concrete evidence about the duration of adjuvant folfox or capox and about other types of chemotherapy and immunotherapy.

Author Biographies

U. Bender, Gerald Bronfman, McGill University
Faculty of Medicine, Department of Oncology
I. Barrera, Gerald Bronfman, McGill University
Faculty of Medicine, Department of Oncology
S. Aghajanyan, Gerald Bronfman, McGill University
Faculty of Medicine, Department of Oncology
P. Kavan, Gerald Bronfman, McGill University
Faculty of Medicine, Department of Oncology
Published
2019-11-19
How to Cite
Bender, U., Rho, Y., Barrera, I., Aghajanyan, S., Acoba, J., & Kavan, P. (2019). Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions. Current Oncology, 26(1). https://doi.org/10.3747/co.26.5605